Filter by:
Topic
Resource Type
Display Only
Showing 109 Results
Commentary: "New York Times Piece on Drug Market Ignores the Data (and Reality)"
NPC's President and CEO John M. O'Brien addresses research using politically expedient shortcuts and the consequences on policy...and patients.
NPC Creates Guiding Principles for Designing and Evaluating Health Care Spending Research and Policies
NPC has developed principles to help evaluate health spending research.
New Moves to Shine More Light Into an Opaque Drug Pricing System
In his latest column for Chain Drug Review, NPC President and CEO John M. O’Brien points to the need for greater transparency in the pharmacy benefit manager-led rebate system.
Drug Price Regulation Trade-offs: Real or Imagined?
NPC hosted a panel at AcademyHealth’s National Health Policy Conference to explore the potential risks and unintended consequences of drug price regulation.
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Week serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies…
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
The Certainty of Uncertainty in Health Technology Assessment
A new Health Affairs Forefront article from Tufts CEVR examines the potential flaws in how health technology assessments identify and report on uncertainty.
NPC in Chain Drug Review: Fostering a More Informed Drug Pricing Conversation
To kick off the new year, NPC's John M. O’Brien writes in Chain Drug Review about the need for a more informed public discussion about the role that prescription drugs play in our health care system…
NPC in RealClearPolicy: Price Setting Bill Is No Panacea for Patients
In a commentary for RealClearPolicy, NPC’s John M. O’Brien explains how the drug pricing deal in the Build Back Better Act could create harmful unintended consequences for patient health and the…
Drug Spending Mirrors Spending on Other Health Care Services
Spending on prescription drugs is not an anomaly but rather follows similar patterns as other health care services. Policy proposals that focus narrowly on constraining drug spending are disregarding…
Health Care Stakeholders Can Learn from Pharmacists’ Patient-Centered Perspective
In a commentary for Pharmacy Times, NPC's John M. O’Brien describes the commitment of pharmacists to ensuring patient access to needed medicines and says other health care stakeholders should follow…
Reference Pricing Isn’t Worth the Risk to Innovation and Patient Health
A Health Affairs Blog co-authored by NPC's Michael Ciarametaro explores the tradeoffs and risks associated with international reference pricing and suggests alternative policy approaches that would…
At the Heart of It: How Innovation Drives Improved Patient Outcomes
In honor of World Heart Day, NPC looks at how innovative medical interventions have vastly improved cardiovascular disease outcomes.
Avoiding Methodological Faults in Real-World Evidence
Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…
Working Together to Deliver Innovation for Patients During COVID-19 and Beyond
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
NPC in Morning Consult: Biopharmaceutical Price Regulation - No Panacea for Patients
In a column published in Morning Consult, NPC's research team explains why potential government involvement in drug pricing would be unlikely to increase patient affordability.
On World Hepatitis Day, Looking at Innovation That Goes Beyond a Pill
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
The Trade-off for Price Controls: Are We Willing to Accept Fewer Medicines?
It's possible to strike a balance between innovation and efficient spending, and to implement policies ensuring that resources are being invested in treatments, procedures and public health efforts…